![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Apotex Pharmachem India Pvt. Ltd Bangalore In, based in Canada, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Olmesartan medoxomil, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R0-CEP 2017-098 - Rev 01
This Chemical Type CEP, issued on January 08, 2020, remains in force until January 20, 2022, ensuring its reliability within the pharmaceutical industry.
Substance Number 2600 associated with this CEP further emphasizes